Vir Biotechnology (VIR) Revenue (2018 - 2026)
Vir Biotechnology (VIR) posted Revenue of $29000.0 for Q1 2026, down 99.95% sequentially from $64.1 million in Q4 2025, and down 99.04% YoY from $3.0 million in Q1 2025.
Vir Biotechnology (VIR) Revenue (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Revenue for 9 years, with the latest figure at $29000.0 in Q1 2026.
- Quarterly Revenue fell 99.04% year-over-year to $29000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.6 million (up 214.24% YoY) and the FY2025 annual result came in at $68.6 million, down 7.61% from the prior year.
- Revenue eased to $29000.0 in Q1 2026 per VIR's latest filing, from $64.1 million in the prior quarter.
- Over five years, Revenue peaked at $1.2 billion in Q1 2022 and troughed at $29000.0 in Q1 2026.
- A 5-year average of $113.0 million and a median of $12.4 million in 2024 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2023: Revenue soared 62271.41% in 2022, then slumped 99.3% in 2023.
- Over 5 years, Revenue stood at $49.4 million in 2022, then plunged by 66.03% to $16.8 million in 2023, then dropped by 26.29% to $12.4 million in 2024, then surged by 417.78% to $64.1 million in 2025, then sank by 99.95% to $29000.0 in 2026.
- According to Business Quant data, Revenue over the past three periods registered $29000.0, $64.1 million, and $240000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 238.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 238.95 Mn |
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | 64.07 Mn |
| Sep 30, 2025 | 240,000.00 |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 3.03 Mn |
| Dec 31, 2024 | 12.37 Mn |
| Sep 30, 2024 | 2.38 Mn |
| Jun 30, 2024 | 3.08 Mn |
| Mar 31, 2024 | 51.70 Mn |
| Dec 31, 2023 | 16.79 Mn |
| Sep 30, 2023 | 2.64 Mn |
| Jun 30, 2023 | 3.80 Mn |
| Mar 31, 2023 | 62.96 Mn |
| Dec 31, 2022 | 49.41 Mn |
| Sep 30, 2022 | 374.56 Mn |
| Jun 30, 2022 | 40.63 Mn |
| Mar 31, 2022 | 1.23 Bn |
| Dec 31, 2021 | 812.75 Mn |
| Sep 30, 2021 | 103.62 Mn |